Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 282-288

  Arrieta, Oscar ^a,b   Vega González, María Teresa ^a   López Macías, Diego ^a   Martínez Hernández, Jorge Negueb ^a   Bacon Fonseca, Ludwing ^a   Macedo Pérez, Eleazar Omar ^a   Ramírez Tirado, Laura Alejandra ^a   Flores Estrada, Diana ^a   de la Garza Salazar, Jaime ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Afatinib; Non small cell lung cancer; Skin toxicities; Tetracycline; Tirosine kinase inhibitors; Toxicity severity

Indexed keywords

AFATINIB; STEROID; SUNSCREEN; TETRACYCLINE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FOLLICULITIS; FOLLOW UP; HUMAN; LOTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN FISSURE; SKIN TOXICITY; TREATMENT RESPONSE; XEROSIS; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; LUNG NEOPLASMS; PATHOLOGY; PRE-EXPOSURE PROPHYLAXIS; RISK FACTOR; SKIN DISEASES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PRE-EXPOSURE PROPHYLAXIS; QUINAZOLINES; RISK FACTORS; SKIN DISEASES; TETRACYCLINE;

EID: 84929518630     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.019     Document Type: Article

References (30)

1. Ferlay J., Shin H.R., Bray F., Parkin D.M. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC cancer base no. 10 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr [accessed 20.04.14].
2. Arrieta O., Guzmán-de Alba E., Alba-López L.F., Acosta-Espinoza A., Alatorre-Alexander J., Alexander-Meza J.F., et al. Consenso de Cáncer de pulmón. Rev Investig Clin 2013, 65:s5-s84.
3. Arrieta O., Nunez-Valencia C., Reynoso-Erazo L., Alvarado S., Flores-Estrada D., Angulo L.P., et al. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 2012, 77:205-211.
4. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
5. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma With EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
6. Sapadin A.N., Fleischmajer R. Tetracyclines nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006, 54:258-265.
7. Boone S.L., Rademaker A., Liu D., Pfeiffer C., Mauro D.J., Lacouture M.E. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007, 72:152-159.
8. Bachet J.B., Peuvrel L., Bachmeyer C., Reguiai Z., Gourraud P.A., Bouche O., et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012, 17:555-568.
9. Yang J.C., Hirsh V., Schuler M., Yamamoto N., O'Byrne K.J., Mok T.S., et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3342-3350.
10. Pérez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005, 23:5235-5246.
11. Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16:1425-1433.
12. Hammond-Thelin L.A. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008, 26:121-159.
13. Sun V. Management of treatment-induced dermatologic toxicities in palliative care. J Hosp Palliat Nurs 2012, 14:80-85.
14. Kiyohara Y., Yamazaki N., Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. Onkologie 2012, 35:747-752.
15. Katakami N., Atagi S., Goto K., Hida T., Horai T., Inoue A., et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013, 31:3335-3341.
16. Deplanque G., Chavaillon J., Vergnenegre A., Falchero L., Fraboulet G., Gervais R., et al. CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010, 28:15s. [suppl; abstr 9019].
17. Jatoi A., Dakhil S.R., Sloan J.A., Kugler J.W., Rowland K.M., Schaefer P.L., et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (supplementary N03CB). Support Care Cancer 2011, 19:1601-1607.
18. Lacouture M.E., Mitchell E.P., Piperdi B., Pillai M.V., Shearer H., Iannotti N., et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28:1351-1357.
19. Peuvrel L., Bachmeyer C., Reguiai Z., Bachet J.B., Andre T., Bensadoun R.J., et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer 2012, 20:909-921.
20. Keating G.M. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 2014, 74:207-221.
21. Wind S., Giessmann T., Jungnik A., Brand T., Marzin K., Bertulis J., et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014, 34:173-182.
22. Wind S., Schmid M., Erhardt J., Goeldner R.G., Stopfer P. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 2013, 52:1101-1109.
23. Dungo R., Keating G.M. Afatinib: first global approval. Drugs 2013, 73:1503-1515.
24. Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:213-222.
25. Janjigian Y.Y., Groen H.J., Horn L., Smit E.F., Fu Y., Wang F., et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011, 29. [suppl; abstr 7525].
26. Janjigian Y.Y., Smit E.F., Horn L. Activity of afatinib/cetuximab in patients with EGFR mutant non-small and acquired resistance to EGFR inhibitors. Ann Oncol 2012, 23. [suppl9; abstr12270].
27. Tiseo M., Andreoli R., Gelsomino F. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2014, 83:265-271.
28. Brahmer J.R., Lee J.W., Trayno A.M. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 2014, 50:302-308.
29. Scope A., Agero A.L., Dusza S.W., Myskowski P.L., Lieb J.A., Saltz L., et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25:5390-5396.
30. Lacouture M.E., Schadendorf D., Chu C.Y., Uttenreuther-Fischer M., Stammberger U., O'Brien D., et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013, 13:721-728.